News - PHRI -

July 7, 2022

Love of puzzles is key to this research role

High school students in the Hamilton area and beyond will learn about a career path in research through a new...

July 5, 2022

South Asians in GTA at high risk for COVID

The COVID-19 pandemic has been particularly devastating for the South Asian community in Peel Region – part of the greater...

July 4, 2022

PHRI at ESC 2022

Several PHRI trials will be presented at European Society of Cardiology (ESC) Congress 2022 in in Barcelona, Spain as well...

June 30, 2022

Margolese Heart Disorders Prize 2022

The University of British Columbia (UBC) Faculty of Medicine has given the Margolese Heart Disorders Prize for 2022 to PHRI...

June 29, 2022

Clinical trial statistics innovator

We were delighted to host American statistician Janet Wittes in Hamilton this week as our 5th Annual Janice Pogue Lectureship...

June 27, 2022

Closing the bench-to-bedside gap

A research program in translational medicine launched this year aims to strengthen the integration of clinical and population health research,...

June 21, 2022

ATLAS and the Weight of Experience

PHRI Senior Scientist Jeff Healey spoke at a webinar today about the results of his trial looking at S-ICD versus...

June 20, 2022

Race, ethnicity, & ancestry in health research

PHRI Investigators Marie Pigeyre and Matt Lanktree co-hosted the OMICS and Epidemiology conference last week, where presenters explored the challenges...

June 6, 2022

ADA outstanding achievement award to Hertzel Gerstein

PHRI Deputy Director and Senior Scientist Hertzel Gerstein received the 2022 Outstanding Achievement in Clinical Diabetes Research Award, presented at...

June 1, 2022

In person again!

Coming together in-person as an organization used to be a regular occurrence for PHRI: research days, lectureships, symposiums and rounds...

May 30, 2022

Take it to the LIMIT

You know a vanguard study has been very successful when one of its key objectives – assessing recruitment potential – ...

May 25, 2022

COMPASS LTOLE supports dual pathway inhibition for vascular protection

PHRI’s COMPASS Long Term Open Label Extension (LTOLE) “further highlights and supports long-term use of [Factor Xa inhibitor anticoagulant] rivaroxaban,...